GLYKOGEN LIMITED

Company Registration Number:
SC547441 (Scotland)

Unaudited statutory accounts for the year ended 31 March 2025

Period of accounts

Start date: 1 April 2024

End date: 31 March 2025

GLYKOGEN LIMITED

Contents of the Financial Statements

for the Period Ended 31 March 2025

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes

GLYKOGEN LIMITED

Directors' report period ended 31 March 2025

The directors present their report with the financial statements of the company for the period ended 31 March 2025

Principal activities of the company

The director presents this annual report and the audited financial statements of the Company for the financial year ended 31 March 2025. Principal Activities The principal activity of the Company during the financial year is that of medical research- Directors The directors who served during the financial year and to the date of this report except as noted, were as follows: Dr Andrew Lane (Resigned 27/08/2025) Derek Cameron Leslie (Resigned 27/08/2025) Dr Kimberley Jane Mackenzie This Director’s Report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption provided by section 415A of the Companies Act 2006. Approved and signed by: Dr Kimberley Jane Mackenzie Director



Directors

The director shown below has held office during the whole of the period from
1 April 2024 to 31 March 2025

Kimberley Jane Mackenzie


The directors shown below have held office during the period of
1 April 2024 to 27 August 2024

Dr Andrew Lane
Derek Cameron Leslie


The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
9 July 2025

And signed on behalf of the board by:
Name: Kimberley Jane Mackenzie
Status: Director

GLYKOGEN LIMITED

Profit And Loss Account

for the Period Ended 31 March 2025

2025 2024


£

£
Turnover: 5,700 551
Cost of sales: ( 2,376 )
Gross profit(or loss): 3,324 551
Administrative expenses: ( 105,517 ) ( 172,638 )
Other operating income: 2,500
Operating profit(or loss): (99,693) (172,087)
Interest receivable and similar income: 19,618 32,974
Profit(or loss) before tax: (80,075) (139,113)
Profit(or loss) for the financial year: (80,075) (139,113)

GLYKOGEN LIMITED

Balance sheet

As at 31 March 2025

Notes 2025 2024


£

£
Fixed assets
Tangible assets: 3 0 1
Total fixed assets: 0 1
Current assets
Debtors: 4 2,865 3,293
Cash at bank and in hand: 9,448 82,603
Total current assets: 12,313 85,896
Net current assets (liabilities): 12,313 85,896
Total assets less current liabilities: 12,313 85,897
Creditors: amounts falling due after more than one year: 5 ( 25,046 ) ( 18,555 )
Total net assets (liabilities): (12,733) 67,342
Capital and reserves
Called up share capital: 34,536 34,536
Share premium account: 949,124 949,124
Profit and loss account: (996,393 ) (916,318 )
Total Shareholders' funds: ( 12,733 ) 67,342

The notes form part of these financial statements

GLYKOGEN LIMITED

Balance sheet statements

For the year ending 31 March 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 9 July 2025
and signed on behalf of the board by:

Name: Kimberley Jane Mackenzie
Status: Director

The notes form part of these financial statements

GLYKOGEN LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2025

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

GLYKOGEN LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2025

  • 2. Employees

    2025 2024
    Average number of employees during the period 1 2

GLYKOGEN LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2025

3. Tangible assets

Land & buildings Plant & machinery Fixtures & fittings Office equipment Motor vehicles Total
Cost £ £ £ £ £ £
At 1 April 2024 113,783 113,783
Additions
Disposals ( 113,783 ) ( 113,783 )
Revaluations
Transfers
At 31 March 2025 0 0
Depreciation
At 1 April 2024 113,782 113,782
Charge for year
On disposals ( 113,782 ) ( 113,782 )
Other adjustments
At 31 March 2025 0 0
Net book value
At 31 March 2025 0 0
At 31 March 2024 1 1

GLYKOGEN LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2025

4. Debtors

2025 2024
£ £
Other debtors 2,865 3,293
Total 2,865 3,293

GLYKOGEN LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2025

5. Creditors: amounts falling due after more than one year note

2025 2024
£ £
Other creditors 25,046 18,555
Total 25,046 18,555

Other taxation and social security: 2025: 5908 2024: 6188 Other creditors: 2025: 19138 2014: 12367